Summit Biomedical Imaging, LLC is a pioneering company based in New York, NY, specializing in the development of fluorescent biomarkers for the early and accurate detection of various cancers. Their proprietary technology, PARPi-FL, specifically targets oral cancer by detecting overexpression of PARP, a DNA repair enzyme commonly found in many cancers.
With a mission to become the world leader in fluorescence-based diagnostics and surgical support, Summit Biomedical Imaging is dedicated to improving patient outcomes by developing innovative fluorescent biomarkers that effectively identify and aid in the removal of cancerous cells. Their research focuses on targeting PARP, an enzyme that is overexpressed in numerous cancers, including lung, colorectal, and cervical cancer.
Generated from the website